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Summary An in vivo 31P NMR spectrum was obtained from each of four human breast tumours. The
phosphomonoester and phosphodiester region of each spectrum consisted of a broad peak. Chemical extracts
from samples of each of the tumours obtained at resection were examined on a high field strength NMR
system. The phosphomonoester region in the spectrum from each extract resolved into three peaks consisting
of phosphocholine, phosphoethanolamine and a nucleoside monophosphate. The phosphodiester region
resolved into two components, glycerophosphorylcholine and glycerophosphorylethanolamine. Comparing the
in vivo and in vitro data from each tumour showed that the contribution of phosphodiester was much lower in
the in vitro spectra. We believe this to be a consequence of phospholipid, which would not appear in the
aqueous extract, contributing to the phosphodiester peak in vivo.
The presence of high concentrations of phosphomonoesters
(PMEs) in human breast tumours has been demonstrated by
several in vitro (Degani et al., 1986; Barzilai et al., 1988;
Merchant et al., 1988) and in vivo (Sijens et al., 1988;
Glaholm et al., 1989) studies using 31P NMR spectroscopy.
Sijens et al. (1988) reported that the positive response of two
breast carcinomas to radiotherapy was accompanied by a
decrease in the PME content of the tumours. Further, quan-
titated changes in PME levels have been observed in a
patient undergoing endocrine treatment and subsequently
chemotherapy for locally advanced breast carcinoma using a
whole body 3lP NMR system Glaholm et al. (1989). These
findings suggest that the PMEs may be sensitive indicators of
tumour cell response to treatment.
In vitro studies of chemical extracts from samples of
human breast tumours (Merchant et al., 1988) and human
cell culture systems (Daly et al., 1987) have suggested that in
breast tumours the PMEs consist principally of phospho-
ethanolamine (PE) with minor contributions from phospho-
choline (PC) and several nucleoside monophosphates.
In order to assess the extent to which in vitro NMR data
are representative of tissue in vivo, and to assist in the
interpretation of therapy-induced changes in in vivo spectra,
we are comparing high resolution NMR spectra from ex-
tracts of human breast tumours with in vivo spectra from the
same tumours prior to operation. The present study shows
preliminary results from four patients which in three cases
are compared with an assessment of necrotic fraction.
In vivo measurements were performed using a 1.5 Tesla
Siemens Magnetom whole body NMR system. Spectral in-
formation specific to the tumour was obtained using a 5 cm
surface coil with Conformal ISIS localisation (Sharp &
Leach, 1989) (dwell time 0.2 ms; repetition time 2 s). In each
case, contiguous slices were taken through the breast to cover
the full extent of the tumour. The ISIS voxel was then chosen
to measure the whole tumour.
A sample weighing about 0.5 g (< 10% of the total
tumour) was obtained from each tumour immediately after
resection and frozen in liquid nitrogen within 8 min. In the
case of tumour 4, we obtained a slice through the tumour
and so this sample contained central as well as peripheral
tissue. For each of the other three tumours, a piece was
sampled from the tumour periphery. After removal of a
section for haematoxylin and eosin staining and subsequent
determination of necrotic fraction, the samples were shat-
tered and ground to a fine powder in a pestle and mortar
under liquid nitrogen. Metabolites were extracted from each
sample using a chloroform/methanol/buffer solvent system
(Graham et al., 1987). D20 (final concentration 10%) and
methylene diphosphonic acid (2.5 gmoles) were added to the
aqueous phase of the extract and the pH was adjusted to 7.4.
NMR analysis of the aqueous extracts was carried out on a
Bruker Spectrospin AC250 spectrometer operating at
101 MHz (for 31P). All measurements were performed under
proton-decoupled conditions in a 10 mm probe. At least
2,000 acquisitions were obtained from each sample. The
parameters used for each acquisition were: sweep width
7937 Hz; acquisition time 0.5 ms; acquisition delay 5 s. (By
comparing peak areas from a spectrum acquired using a
repetition time of 20s with those from a spectrum obtained
using a 5 s repetition time we have shown that all the spectral
components in the aqueous phase of the extracts achieved
full relaxation in 5 s). Acquisitions were performed at 20°C.
(The extracted sample components were shown to be stable
at this temperature for at least 2 weeks). Peak assignments
were verified in sample extracts by repeating the NMR
mesurement with the addition of commercially obtained
metabolites.
Figure 1 shows the in vivo and in vitro spectra from each
tumour. The in vivo spectra show prominent PME and phos-
phodiester (PDE) peaks. Nucleotide triphosphates and
diphosphates (NTP and NDP) are present and also inorganic
phosphorus (Pi). Phosphocreatine (PCr) is visible in the in
vivo spectrum from tumours 2 and 4, however in both these
cases the selected region was within 0.5 cm of the chest wall,
thus contamination due to respiratory motion cannot be
excluded.
The in vitro spectra from each tumour show that the high
energy moieties, NTP and NDP, are less prominent whilst Pi
is increased. This may be the result of degradation occurring
during the inevitable time delay between the excision and
freezing of the tumours. As well as NTP and NDP, the alpha
NTP peak contains resonances from nicotinamide adenine
dinucleotide (NAD). NAD appears to be particularly stable
since in extracts carried out in this laboratory where most of
the NTP has disappeared, NAD is still present.
Diphosphodiester (DPDE) is present adjacent to the alpha
NTP peak in some of the in vitro spectra. In human breast
tumours DPDE has been shown to consist primarily of
nucleoside diphosphosugars (Merchant et al., 1988).
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Table I Areas of peaks, realtive to total NMR visible phosphorus,
in in vivo spectra (± associated uncertainty estimate (goodness of fit
of the Lorentzian model)) (a) and in vitro spectra (b) of four human
breast tumours (units: % total phosphorus)
(a)
Tumour
Peak 1 2 3 4
PME 17 1 13±2 14±2 17 1
Pi 9 1 9±2 11 2 4 1
PDE 40±2 25±3 33±2 36±3
PCr 9±1 5±1
gamma NTP 11+± 1 16±3 13 1 14±2
alpha NTP 18±2 17±3 15±1 19±2
beta NTP 5±1 12±3 9±1 11±2
Sample
volume (cm3) 65 129 89 90
(b)
Tumour
Compound 1 2 3 4
PE 10 22 25 36
PC 8 13 5 3
AMP 4 2 10 3
Pi 41 37 52 29
GPE 4 - - 1
GPC 13 1 1 1
gamma NTP 5 5 - 5
alpha NTP 13 15 8 16
DPDE - 1 - 3
beta NTP 2 5 3
Necrotic
fraction Up to 50% <10% None Not done
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Figure 1 In vivo (upper) and in vitro (lower) spectra from four
human breast tumours a, tumour 1; b, tumour 2; c, tumour 3; d,
tumour 4.
Three significant components are observed in the PME
region of each of the tumours. We have confirmed that two
of the components are PE and PC which are anabolites of
the phospholipids, phosphatidylethanolamine and phospha-
tidylcholine respectively. The areas, relative to total NMR
visible phosphorus, of the peaks in both the in vivo and in
vitro spectra from each of the tumours are shown in Table I.
For the in vitro spectra, peak areas were calculated by peak
integration using software available in the spectrometer. A
manual simulataneous peak fitting routine, developed in this
laboratory, was used to estimate the peak areas in the in vivo
spectra. This provides an associated uncertainty based on the
goodness of fit of the Lorentzian model and on spectral
signal to noise. This value is included in the table.
The percentage of PME in the in vivo spectrum from each
tumour is much lower than in the in vitro spectrum.
Vermeulen et al. (1987) showed that in in vivo spectra of
human brain the TI relaxation time of the PME peak, which
is also known to consist primarily of PE and PC (Pettegrew
et al., 1987), is greater than 2 s. It is therefore probable that
the much greater relative concentrations of the PME com-
ponents in the in vitro spectra from each tumour is due to
signal suppression, which occurs in vivo as a consequence of
the shorter repetition time used for the in vivo measurements.
The spectral components in the extracts may also have
shorter TI relaxation times than is the case in vivo since the
solvent mixture in the aqueous phase contains about 50%
methanol.
Although the peak areas, relative to total NMR visible
phosphorous, of the PME peak in the in vivo spectra show
little inter-tumour variation, the ratio of PC to PE varies
profoundly between each of the four tumours. The relative
concentrations of these two compounds may reflect
differences in the relative content of phosphatidylcholine and
phosphatidylethanolamine in the membranes of each of these
tumours. We are currently investigating this possibility.
The third peak in the PME region of each tumour is a
nucleotide monophosphate (NMP). The concentration of
NMP and Pi is particularly high in tumour 3 whereas NTP is
almost depleted. This suggests that most of the NMP in the
in vitro spectra has been derived from the hydrolysis of NTP
during the short delay between resection and freezing of this
tumour. We have shown that PE, PC, GPE and GPC were
stable in a human breast tumour left at room temperature for
up to 90min (Smith et al., 1990a).
The two resonances in the PDE region consist of
glycerophosphorylethanolamine (GPE) and glycerophos-
phorylcholine (GPC) which are catabolites of phospha-
tidylethanolamine and -choline respectively. From the table it
can be seen that the relative contribution of PDEs in the in
vitro spectra of tumours 2, 3 and 4 is much lower than in the516 T.A.D. SMITH et al.
in vivo spectra. We are currently investigating variations in
the concentrations of phosphorus containing metabolites
within a tumour and have found that the levels of such
metabolites, relative to total phosphorus, are remarkably
consistent throughout breast tumours (Smith et al., 1990b).
Further, since the sample from tumour 4 consists of central
as well as peripheral tumour tissue, it is unlikely that the
discrepancy in the intensities of the PDE components
between the in vivo and the in vitro spectra, at least in tumour
4, reflects selective tumour sampling. The most likely ex-
planation is that phospholipids contribute to the in vivo PDE
peak of human breast tumours. Phospholipids have been
shown to contribute significantly to the in vivo NMR spectra
of both liver (Bates et al., 1989; Murphy et al., 1989) and
brain (Cerden et al., 1986).
The necrotic fraction in three of the tumours is shown in
the table. Tumour 1 is particularly necrotic compared with
tumours 2 and 3. Evanochko et al. (1984) have suggested
that the concentrations of GPE and GPC may reflect the
necrotic fraction of a tumour as a consequence of phos-
pholipid degradation. Interestingly the relative concentrations
of GPE and GPC in tumour 1, unlike tumours 2 and 3, are
very high.
In summary, by comparing in vitro 31P NMR spectra of
chemical extracts of human breast carcinomas with in vivo
NMR measurements from the same patients, the present
work has shown: firstly, that the in vivo spectra of human
breast tumours are not composed primarily of GPE and
GPC, but contain dominating resonances from non-water
soluble components which are presumably phospholipid in
nature. Secondly we have confirmed that the PME peaks
consist primarily of PC and PE and that the peak areas,
relative to total phosphorous, of PE and PC vary profoundly
between each tumour. The relative concentrations of these
two compounds may yield useful information about the
phospholipid content of breast tumour cell membranes.
Further, a large increase in the intracellular concentration of
PC (Besterman et al., 1986) has been shown to be one of the
earliest responses of tumour cells to growth factors. Thus the
ability to distinguish between the components in the PME
region of in vivo spectra from human breast tumours, cur-
rently by in vitro extract measurement and in the future by
proton decoupled in vivo 31P NMR measurements (Luyten et
al., 1989) may be of considerable value in monitoring and
predicting the response of tumours in vivo.
This work was supported by the Cancer Research Campaign and by
the Royal Marsden Hospital.
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